Prospective evaluation of ID NOW COVID-19 assay used as point-of-care test in an emergency department. 2021

Jean-Claude NguyenVan, and Camille Gerlier, and Benoît Pilmis, and Assaf Mizrahi, and Gauthier Péan de Ponfilly, and Amir Khaterchi, and Vincent Enouf, and Olivier Ganansia, and Alban Le Monnier
Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France. Electronic address: jcnguyen@ghpsj.fr.

Rapid testing for COVID-19 has been clearly identified as an essential component of the strategy to control the SARS-CoV-2 epidemic, worldwide. The ID NOW COVID-19 assay is a simple, user-friendly, rapid molecular biology test based on nicking and extension amplification reaction (NEAR). The aim of this study was to evaluate the ID NOW COVID-19 assay when used as a point-of-care test (POCT) in our Emergency Department (ED). This prospective study enrolled 395 consecutive patients; paired nasopharyngeal swabs were collected from each study participant. The first swab was tested with the ID NOW COVID-19 assay at the point-of-care by ED nurses. The second swab was diluted in viral transport medium (VTM) and sent to the clinical microbiology department for analysis by both the RT-PCR Simplexa test COVID-19 Direct assay as the study reference method, and the ID NOW COVID-19 assay performed in the laboratory. Nasopharyngeal swabs directly tested with the ID NOW COVID-19 assay yielded a sensitivity, specificity, PPV and NPV of 98.0%, 97.5%, 96.2% and 98.7%, respectively, in comparison with the RT-PCR study reference assay. When the ID NOW COVID-19 assay was performed in the laboratory using the VTM samples, the sensitivity decreased to 62.5% and the NPV to 79.7%. Three false negative test results were reported with the ID NOW COVID-19 assay when performed using undiluted swabs directly in the ED; these results were obtained from patients with elevated CT values (> 30). We demonstrated that the ID NOW COVID-19 assay, performed as a point of care test in the ED using dry swabs, provides a rapid and reliable alternative to laboratory-based RT-PCR methods.

UI MeSH Term Description Entries
D009305 Nasopharynx The top portion of the pharynx situated posterior to the nose and superior to the SOFT PALATE. The nasopharynx is the posterior extension of the nasal cavities and has a respiratory function. Rhinopharynx,Choanae,Nasopharynges,Nasopharynxes,Rhinopharynges,Rhinopharynxes
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D004636 Emergency Service, Hospital Hospital department responsible for the administration and provision of immediate medical or surgical care to the emergency patient. Emergency Outpatient Unit,Emergency Services Utilization,Hospital Emergency Room,Hospital Emergency Service,Hospital Emergency Services Utilization,Accident and Emergency Department,Emergency Departments,Emergency Hospital Service,Emergency Room,Emergency Units,Emergency Ward,Hospital Service Emergency,Service, Hospital Emergency,Department, Emergency,Departments, Emergency,Emergencies, Hospital Service,Emergency Department,Emergency Hospital Services,Emergency Outpatient Units,Emergency Room, Hospital,Emergency Rooms,Emergency Rooms, Hospital,Emergency Services, Hospital,Emergency Unit,Emergency Wards,Emergency, Hospital Service,Hospital Emergency Rooms,Hospital Emergency Services,Hospital Service Emergencies,Hospital Service, Emergency,Hospital Services, Emergency,Outpatient Unit, Emergency,Outpatient Units, Emergency,Room, Emergency,Room, Hospital Emergency,Rooms, Emergency,Rooms, Hospital Emergency,Service Emergencies, Hospital,Service Emergency, Hospital,Service, Emergency Hospital,Services Utilization, Emergency,Services Utilizations, Emergency,Services, Emergency Hospital,Services, Hospital Emergency,Unit, Emergency,Unit, Emergency Outpatient,Units, Emergency,Units, Emergency Outpatient,Utilization, Emergency Services,Ward, Emergency,Wards, Emergency
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000067716 Point-of-Care Testing Allows patient diagnoses in the physician’s office, in other ambulatory setting or at bedside. The results of care are timely, and allow rapid treatment to the patient. (from NIH Fact Sheet Point-of-Care Diagnostic Testing, 2010.) Bedside Testing,Point-Of-Care Diagnostic Testing,Point-Of-Care Diagnostic Tests,Point-Of-Care Diagnostics,Point-Of-Care Test,Point-Of-Care Tests,Point of Care Testing,Diagnostic Test, Point-Of-Care,Diagnostic Testing, Point-Of-Care,Diagnostic Tests, Point-Of-Care,Diagnostic, Point-Of-Care,Diagnostics, Point-Of-Care,Point Of Care Diagnostic Testing,Point Of Care Diagnostic Tests,Point Of Care Diagnostics,Point Of Care Test,Point Of Care Tests,Point-Of-Care Diagnostic,Point-Of-Care Diagnostic Test,Test, Point-Of-Care,Test, Point-Of-Care Diagnostic,Testing, Bedside,Testing, Point-Of-Care Diagnostic,Testing, Point-of-Care,Tests, Point-Of-Care,Tests, Point-Of-Care Diagnostic
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000086742 COVID-19 Testing Diagnosis of COVID-19 by assaying bodily fluids or tissues for the presence of COVID-19 antibodies, SARS-COV-2 antigens or the VIRAL RNA of SARS-COV-2. 2019 Novel Coronavirus Disease Testing,2019 Novel Coronavirus Testing,2019-nCoV Disease Testing,2019-nCoV Infection Testing,2019-nCoV Testing,COVID-19 Diagnostic Testing,COVID-19 Virus Testing,COVID19 Testing,COVID19 Virus Testing,Coronavirus Disease 2019 Testing,Coronavirus Disease-19 Testing,SARS Coronavirus 2 Testing,SARS-CoV-2 Testing,Severe Acute Respiratory Syndrome Coronavirus 2 Testing,2019 nCoV Disease Testing,2019 nCoV Infection Testing,2019 nCoV Testing,2019-nCoV Disease Testings,2019-nCoV Infection Testings,2019-nCoV Testings,COVID 19 Diagnostic Testing,COVID 19 Testing,COVID 19 Virus Testing,COVID-19 Diagnostic Testings,COVID-19 Testings,COVID-19 Virus Testings,COVID19 Testings,COVID19 Virus Testings,Coronavirus Disease 19 Testing,Coronavirus Disease-19 Testings,Diagnostic Testing, COVID-19,Disease Testing, 2019-nCoV,Infection Testing, 2019-nCoV,SARS CoV 2 Testing,SARS-CoV-2 Testings,Testing, 2019-nCoV,Testing, 2019-nCoV Disease,Testing, 2019-nCoV Infection,Testing, COVID-19,Testing, COVID-19 Virus,Testing, COVID19,Testing, COVID19 Virus,Testing, Coronavirus Disease-19,Testing, SARS-CoV-2,Virus Testing, COVID-19,Virus Testing, COVID19
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity

Related Publications

Jean-Claude NguyenVan, and Camille Gerlier, and Benoît Pilmis, and Assaf Mizrahi, and Gauthier Péan de Ponfilly, and Amir Khaterchi, and Vincent Enouf, and Olivier Ganansia, and Alban Le Monnier
June 2022, Microbiology spectrum,
Jean-Claude NguyenVan, and Camille Gerlier, and Benoît Pilmis, and Assaf Mizrahi, and Gauthier Péan de Ponfilly, and Amir Khaterchi, and Vincent Enouf, and Olivier Ganansia, and Alban Le Monnier
July 2023, Journal of clinical microbiology,
Jean-Claude NguyenVan, and Camille Gerlier, and Benoît Pilmis, and Assaf Mizrahi, and Gauthier Péan de Ponfilly, and Amir Khaterchi, and Vincent Enouf, and Olivier Ganansia, and Alban Le Monnier
February 2024, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Jean-Claude NguyenVan, and Camille Gerlier, and Benoît Pilmis, and Assaf Mizrahi, and Gauthier Péan de Ponfilly, and Amir Khaterchi, and Vincent Enouf, and Olivier Ganansia, and Alban Le Monnier
December 2021, Journal of the American College of Emergency Physicians open,
Jean-Claude NguyenVan, and Camille Gerlier, and Benoît Pilmis, and Assaf Mizrahi, and Gauthier Péan de Ponfilly, and Amir Khaterchi, and Vincent Enouf, and Olivier Ganansia, and Alban Le Monnier
December 2021, Diagnostic microbiology and infectious disease,
Jean-Claude NguyenVan, and Camille Gerlier, and Benoît Pilmis, and Assaf Mizrahi, and Gauthier Péan de Ponfilly, and Amir Khaterchi, and Vincent Enouf, and Olivier Ganansia, and Alban Le Monnier
December 2021, Journal of medical virology,
Jean-Claude NguyenVan, and Camille Gerlier, and Benoît Pilmis, and Assaf Mizrahi, and Gauthier Péan de Ponfilly, and Amir Khaterchi, and Vincent Enouf, and Olivier Ganansia, and Alban Le Monnier
September 2021, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
Jean-Claude NguyenVan, and Camille Gerlier, and Benoît Pilmis, and Assaf Mizrahi, and Gauthier Péan de Ponfilly, and Amir Khaterchi, and Vincent Enouf, and Olivier Ganansia, and Alban Le Monnier
November 2023, Diagnostics (Basel, Switzerland),
Jean-Claude NguyenVan, and Camille Gerlier, and Benoît Pilmis, and Assaf Mizrahi, and Gauthier Péan de Ponfilly, and Amir Khaterchi, and Vincent Enouf, and Olivier Ganansia, and Alban Le Monnier
April 2023, Diagnostic microbiology and infectious disease,
Jean-Claude NguyenVan, and Camille Gerlier, and Benoît Pilmis, and Assaf Mizrahi, and Gauthier Péan de Ponfilly, and Amir Khaterchi, and Vincent Enouf, and Olivier Ganansia, and Alban Le Monnier
December 2004, Communicable disease and public health,
Copied contents to your clipboard!